BioTek’s Synergy H1 Receives HTRF Certification
News Sep 23, 2010
BioTek Instruments announces that their latest addition to the patent-pending Hybrid Microplate Reader family has received HTRF® certification from Cisbio Bioassays.
The Synergy™ H1 Hybrid Multi-Mode Microplate Reader is certified to meet or exceed strict performance and functional criteria for optimal HTRF results, which means that life science and drug discovery researchers are assured of increased productivity and extended flexibility for this assay platform.
Synergy H1 offers researchers a choice of monochromators or filters or both detection technologies in one compact unit. At its core, Synergy H1 is a monochromator-based multi-mode microplate reader with a quadruple grating architecture for robust performance and flexibility.
The optional HTRF-certified filter-based module may be added at any time to upgrade Synergy H1 to an advanced Hybrid system with broad current and future application range.
A dual-reagent injection system automates inject-and-read assays such as ion channel and flash luminescence assays, and Synergy H1 is compatible with BioTek’s Take3™ Multi-Volume Plate that measures up to sixteen 2 µL samples. Integrated Gen5™ Data Analysis Software provides advanced reader control, data analysis, graphing and reporting.
In addition to HTRF assays, Synergy H1 may be used for UV-Vis absorbance, top and bottom fluorescence, luminescence, fluorescence polarization, time-resolved fluorescence, FRET and BRET applications.
CRISPR Reveals New Targets for Promising Cancer DrugsNews
Novel screening method identifies new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising new class of cancer immunotherapy.READ MORE
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Big-Data Analysis Points Toward New Drug Discovery MethodNews
A research team has developed a computational method to systematically probe massive amounts of open-access data to discover new ways to use drugs, including some that have already been approved for other uses.
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018